Acute Porphyria Drug Database

A02BA01 - Cimetidine
Not porphyrinogenic
NP

Rationale
Only metabolised to a minor extent. Unspecific CYP-inhibitor (CYPs 2C9, 11B1, 1A2, 2C19, 2D6, 2E1, 3A4). To be observed: imidazole is an CYP 2E1 inducer! Several references consider it safe or probably safe. Also repeatedly used without porphyric side effects.
Chemical description
(To be edited, initial data ST OCT 04) Imidazole histamine-receptor antagonist used in ventricular hyperacidity. Slightly (10-15 %) metabolized enzymatically to sulfdioxide. In large parts excreted unchanged in urine. Unspecific CYP-inhibitor which has been used in the treatment of the acute porphyric attack. MFM James, RJ Hift. Porphyrias. Br J Anaesth 2000; 85, 143-5: use with care South African list: use with care. French list: authorized. Merck Index: safe. Siepmann M et al. Cimetidine in treatment of acute intrmittent porphyria. Z Gastroenterol. 31:246, 1993: safe. D.Andersson: Frequently used without porphyric side effects. C.Andersson; patient reports: tolerated (n=2)
IPNet drug reports
Uneventful use reported in 3 patients with acute porphyria.

Similar drugs
Explore alternative drugs in similar therapeutic classes A02B / A02BA or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙